WEBINAR ON DEMAND
Duration: 1 hour

Mastering chemistry, manufacturing, and control complexities for in vivo CAR-T therapies, including messenger and circular RNAs, poses a new challenge for drug development. Moving from “simple” mRNA vaccines with “naked” LNPs to complex mRNA therapeutics delivered by targeted LNPs requires knowledge of quality requirements, delivery challenges, and opportunities for an innovative process design.

This webinar explores the critical factors that define success for in vivo CAR-T. Industry experts discuss analytical challenges and opportunities influencing the future of these therapies. Highlights include:

• Understanding the quality requirements for the development and the manufacturing of complex RNA therapies.
• How to design an innovative strategy from development to IND for your RNA in vivo CAR-T therapies.
• How to address delivery challenges from a quality and reproducibility perspective.
• Identifying the major challenges in the design and scale-up of your in vivo CAR-T therapies.

SPEAKERS

Alexander Schwanger
Director, LNP Process Development & AD/PD Coordination
Lonza
 

Marta Margutti
Associate Director, Technical Sales & Proposals
Lonza
​